CRUK trial is a decisive move away from one-size-fits-all approach
By Nuala Moran
Monday, April 21, 2014
LONDON A new era in personalized treatment of cancer begins later this year in the UK with the opening of a phase II trial that will test at least 12 drugs in a single study. Patients with advanced lung cancer will be stratified according to the genetics of their tumors to receive one of the 12 drugs targeted to specific mutations.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.